EP1726310A4 - Medicament pour la therapie de cancers - Google Patents

Medicament pour la therapie de cancers

Info

Publication number
EP1726310A4
EP1726310A4 EP05720394A EP05720394A EP1726310A4 EP 1726310 A4 EP1726310 A4 EP 1726310A4 EP 05720394 A EP05720394 A EP 05720394A EP 05720394 A EP05720394 A EP 05720394A EP 1726310 A4 EP1726310 A4 EP 1726310A4
Authority
EP
European Patent Office
Prior art keywords
medicine
lactoferrin
cancer therapy
drug
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP05720394A
Other languages
German (de)
English (en)
Other versions
EP1726310B1 (fr
EP1726310A1 (fr
Inventor
Kiyohiko Hatake
Yasuhito Terui
Yuji Mishima
Akio Yamada
Takuma Sakurai
Takehito Itoh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morinaga Milk Industry Co Ltd
Original Assignee
Morinaga Milk Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morinaga Milk Industry Co Ltd filed Critical Morinaga Milk Industry Co Ltd
Publication of EP1726310A1 publication Critical patent/EP1726310A1/fr
Publication of EP1726310A4 publication Critical patent/EP1726310A4/fr
Application granted granted Critical
Publication of EP1726310B1 publication Critical patent/EP1726310B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP05720394A 2004-03-19 2005-03-09 Medicament pour la therapie de cancers Not-in-force EP1726310B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004080454 2004-03-19
PCT/JP2005/004123 WO2005089788A1 (fr) 2004-03-19 2005-03-09 Médicament pour la thérapie de cancers

Publications (3)

Publication Number Publication Date
EP1726310A1 EP1726310A1 (fr) 2006-11-29
EP1726310A4 true EP1726310A4 (fr) 2009-06-24
EP1726310B1 EP1726310B1 (fr) 2012-01-18

Family

ID=34993444

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05720394A Not-in-force EP1726310B1 (fr) 2004-03-19 2005-03-09 Medicament pour la therapie de cancers

Country Status (14)

Country Link
US (1) US7419667B2 (fr)
EP (1) EP1726310B1 (fr)
JP (1) JP3998702B2 (fr)
KR (1) KR100773259B1 (fr)
CN (2) CN101444624B (fr)
AT (1) ATE541581T1 (fr)
AU (1) AU2005224209B2 (fr)
CA (1) CA2533753C (fr)
DK (1) DK1726310T3 (fr)
ES (1) ES2381189T3 (fr)
HK (2) HK1128113A1 (fr)
NZ (1) NZ544448A (fr)
PT (1) PT1726310E (fr)
WO (1) WO2005089788A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ555134A (en) * 2004-11-19 2010-07-30 Fonterra Co Operative Group Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer
CA2673484A1 (fr) * 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. Analogues peptidiques de t-140 presentant une activite superagoniste par rapport a cxcr4 destines a une cancerotherapie
US20100204144A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeutic agents
MX2011013459A (es) 2009-06-14 2012-05-08 Biokine Therapeutics Ltd Terapia de peptido para incrementar los niveles de plaquetas.
EP2841084B1 (fr) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Peptide antagoniste de cxcr4 et son utilisation pour le traitment de tumeurs pulmonaires
KR101455306B1 (ko) * 2012-07-17 2014-10-27 엘에스엠 주식회사 세포 증식 촉진용 사람 락토페린의 펩신 가수분해물 및 이의 제조 방법
US20170296629A1 (en) * 2014-10-08 2017-10-19 Keio University Inhibitor of extracellular trap formation in leukocyte
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
IL258931B (en) * 2015-10-06 2022-09-01 Univ Minnesota Medicinal compounds and methods
ES2830726T3 (es) 2016-02-23 2021-06-04 Biolinerx Ltd Método para seleccionar un régimen de tratamiento para la leucemia mieloide aguda (LMA)
CN113354726B (zh) * 2021-06-11 2022-12-27 南方科技大学 乳铁蛋白活性肽及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656591A (en) * 1992-01-23 1997-08-12 Morinaga Milk Industry Co., Ltd. Antimicrobial agents and method for treating products therewith
WO1998006424A1 (fr) * 1996-08-15 1998-02-19 Morinaga Milk Industry Co., Ltd. Inhibiteurs des metastases cancereuses administres par voie orale

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6351337A (ja) 1986-08-22 1988-03-04 Snow Brand Milk Prod Co Ltd 抗腫瘍剤
JPS63186260A (ja) 1987-01-28 1988-08-01 Minolta Camera Co Ltd 作像装置
JP2818056B2 (ja) * 1990-09-07 1998-10-30 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤
JP3110078B2 (ja) 1991-06-21 2000-11-20 森永乳業株式会社 高純度抗菌性ペプチドの大量製造法
JP3207647B2 (ja) 1993-12-21 2001-09-10 森永乳業株式会社 ＩｇＧおよびＩｇＭクラスの抗体産生を促進する免疫賦活剤
JP3738042B2 (ja) 1994-05-17 2006-01-25 森永乳業株式会社 非経口用抗腫瘍剤
JP3506274B2 (ja) * 1994-09-01 2004-03-15 雪印乳業株式会社 新規ペプチドおよび免疫賦活剤
JP3693377B2 (ja) 1995-04-20 2005-09-07 森永乳業株式会社 生体内で感染防御作用を有するペプチド混合物と、このペプチド混合物を含有する組成物
JP2002515893A (ja) * 1997-02-03 2002-05-28 ファーミング インテレクチュアル プロパティ ビーブイ ヒトラクトフェリンおよびその改変体の有用な特性
GB9818938D0 (en) 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
JP2000229881A (ja) 1999-02-10 2000-08-22 Morinaga Milk Ind Co Ltd 癌疾患の予後改善剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656591A (en) * 1992-01-23 1997-08-12 Morinaga Milk Industry Co., Ltd. Antimicrobial agents and method for treating products therewith
WO1998006424A1 (fr) * 1996-08-15 1998-02-19 Morinaga Milk Industry Co., Ltd. Inhibiteurs des metastases cancereuses administres par voie orale

Also Published As

Publication number Publication date
HK1128113A1 (en) 2009-10-16
CN101444624B (zh) 2012-10-10
JPWO2005089788A1 (ja) 2008-01-31
KR100773259B1 (ko) 2007-11-05
PT1726310E (pt) 2012-04-27
CN101444624A (zh) 2009-06-03
WO2005089788A1 (fr) 2005-09-29
US20060204501A1 (en) 2006-09-14
EP1726310B1 (fr) 2012-01-18
ES2381189T3 (es) 2012-05-23
DK1726310T3 (da) 2012-05-07
KR20060095899A (ko) 2006-09-04
HK1093436A1 (en) 2007-03-02
ATE541581T1 (de) 2012-02-15
CA2533753A1 (fr) 2005-09-29
AU2005224209B2 (en) 2007-04-19
AU2005224209A1 (en) 2005-09-29
JP3998702B2 (ja) 2007-10-31
US7419667B2 (en) 2008-09-02
EP1726310A1 (fr) 2006-11-29
CA2533753C (fr) 2012-10-16
CN1838965A (zh) 2006-09-27
CN1838965B (zh) 2011-07-06
NZ544448A (en) 2009-10-30

Similar Documents

Publication Publication Date Title
HK1093436A1 (en) Medicine for cancer therapy
HK1109876A1 (en) Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation
LUC00011I1 (fr)
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
NZ595313A (en) The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
NZ605871A (en) Treatment of sanfilippo syndrome type b
AU2019215782A1 (en) Method for delivering drug to muscle
HUP0102489A2 (hu) Biokémiai anyagok alkalmazása emberi test szerveiben található simaizomsejtek összehúzódása okozta egészségi állapotok megelőzésére és kezelésére alkalmas készítményekben
ATE306290T1 (de) Tragbare vorrichtung zur verabreichung von medikamenten und dergleichen
WO2007087154A3 (fr) Méthodes destinées à renforcer les effets thérapeutiques d'une neurotoxine
MX2007005581A (es) Regimen de dosificacion mejorada de temozolomida para el tratamiento de cancer con base en el nivel de o6-metilguanidi-adn metiltransferasa del paciente.
WO2007018588A8 (fr) Composition pharmaceutique stable comprenant la forme iv de linézolide
GB2453491A (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
SE0301663D0 (sv) Analysmetod för infusionsläkemedel
WO2003063780A3 (fr) Composition therapeutique pour le traitement du cancer par depletion de l'arginine
WO2006134135A3 (fr) Methode nutritionnelle
ATE453388T1 (de) Calciumtrifluoroacetat zur bereitung antiangiogenetischer arzneimittel
EP1374907A3 (fr) Système véhiculaire et de délivrance de médicaments
Borodin et al. Effect of the enteric sorbent noolit on the psychoemotional status in mice
RU2003110474A (ru) Способ лечения хронического тонзиллита
UA2701U (uk) Спосіб використання лікарських засобів та біологічно активних добавок без відома хворого
GEP20043317B (en) Ointment for Treatment of Purulent Diseases, Festering Wounds and Burns

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060116

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20090528

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/47 20060101ALI20090515BHEP

Ipc: A61P 35/00 20060101ALI20090515BHEP

Ipc: A61K 38/00 20060101ALI20090515BHEP

Ipc: A23L 1/305 20060101ALI20090515BHEP

Ipc: A61K 38/16 20060101AFI20051006BHEP

Ipc: A61P 43/00 20060101ALI20090515BHEP

Ipc: A61P 37/04 20060101ALI20090515BHEP

17Q First examination report despatched

Effective date: 20091216

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ITOH, TAKEHITO

Inventor name: TERUI, YASUHITO

Inventor name: SAKURAI, TAKUMA

Inventor name: YAMADA, AKIO

Inventor name: HATAKE, KIYOHIKO

Inventor name: MISHIMA, YUJI

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RTI1 Title (correction)

Free format text: DRUG FOR CANCER THERAPY

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Ref country code: AT

Ref legal event code: REF

Ref document number: 541581

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120215

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602005032260

Country of ref document: DE

Effective date: 20120322

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. AG PATENT- UND MARKENANWAELTE VSP

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20120417

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2381189

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20120523

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20120400891

Country of ref document: GR

Effective date: 20120518

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20120118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120118

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120518

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120118

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120118

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120118

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120118

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120118

26N No opposition filed

Effective date: 20121019

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602005032260

Country of ref document: DE

Effective date: 20121019

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20130321

Year of fee payment: 9

Ref country code: FI

Payment date: 20130313

Year of fee payment: 9

Ref country code: FR

Payment date: 20130408

Year of fee payment: 9

Ref country code: ES

Payment date: 20130326

Year of fee payment: 9

Ref country code: CH

Payment date: 20130322

Year of fee payment: 9

Ref country code: DK

Payment date: 20130320

Year of fee payment: 9

Ref country code: IE

Payment date: 20130322

Year of fee payment: 9

Ref country code: DE

Payment date: 20130321

Year of fee payment: 9

Ref country code: MC

Payment date: 20130313

Year of fee payment: 9

Ref country code: GB

Payment date: 20130305

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20130314

Year of fee payment: 9

Ref country code: NL

Payment date: 20130320

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20130313

Year of fee payment: 9

Ref country code: PT

Payment date: 20120417

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20130320

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20130327

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120309

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050309

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20140909

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602005032260

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20140331

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20141001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140309

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 541581

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140309

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20140309

REG Reference to a national code

Ref country code: GR

Ref legal event code: ML

Ref document number: 20120400891

Country of ref document: GR

Effective date: 20141002

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140310

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20141128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140909

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602005032260

Country of ref document: DE

Effective date: 20141001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140309

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140331

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141001

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140331

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141002

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140331

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140309

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140309

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140309

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20150429

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140310

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140331